Tomohiro Iwasawa

Tomohiro Iwasawa

Auto-generated profile, based on publicly available information

Tomohiro Iwasawa

Department of Urology Keio University School of Medicine Tokyo Japan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2026 in International Journal of Urology
Verified
Journal Article
Closed access
TITomohiro Iwasawa
Tomohiro Iwasawa
TTTakuya Tsujino
Takuya Tsujino
STShigehiro Tsukahara
Shigehiro Tsukahara
Hiroshi FukushimaHiroshi Fukushima
Hiroshi Fukushima
DIDaisuke Ito
Daisuke Ito
Fumihiko UrabeFumihiko Urabe
Fumihiko Urabe

4 November 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
KIKota Itahashi
Kota Itahashi
AKAkihito Kawazoe
Akihito Kawazoe
THTadayoshi Hashimoto
Tadayoshi Hashimoto
YYYue Yan
Yue Yan
TITakuma Irie
Takuma Irie
KSKohei Shitara
Kohei Shitara
Previous studies combining the multikinase inhibitor regorafenib with a PD-1 inhibitor showed promising activity in gastric cancer. We conducted a phase 1b/2 trial (NCT05394740) of first-line regorafenib, nivolumab, and chemotherapy in 30 patients with mismatch repair–proficient gastric cancer and investigated its impact on the tumor microenvironment. The primary end point was met; 22 of 30 patients showed objective tumor response (73%; 80% confidence interval, 60.3 to 83.8). Single-cell RNA and T cell receptor sequencing were performed on biopsy samples at baseline, during treatment, and at disease progression. The combination treatment increased tumor antigen–reactive CD8 + T cells and M1-like proinflammatory macrophages and decreased immunosuppressive and tumor-promoting populations, including activated CCR8 + regulatory T cells, LRRC15 + cancer-associated fibroblasts (CAFs), RGS5 + pericytes, and APLN + tip cells. At progression, LRRC15 + CAFs and APLN + tip cells remained reduced, activated CCR8 + regulatory T cells reexpanded, and additional treatment-resistant subsets emerged, including APOC1 + lipid-associated macrophages. In murine models of acquired resistance, therapeutic targeting of these suppressive immune cell populations with antibodies against CCR8 or TREM2 in combination with PD-1 blockade restored antitumor immunity. These findings demonstrate dynamic remodeling of the tumor microenvironment and suggest potential therapeutic targets.